Equities research analysts expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to report earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Spring Bank Pharmaceuticals’ earnings. Spring Bank Pharmaceuticals posted earnings of ($0.28) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.6%. The firm is expected to issue its next quarterly earnings results on Wednesday, July 29th.
According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($1.57) per share for the current fiscal year. For the next year, analysts forecast that the company will post earnings of ($0.89) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its earnings results on Thursday, May 7th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.29).
Shares of Spring Bank Pharmaceuticals stock traded down $0.11 during midday trading on Friday, hitting $1.53. The company’s stock had a trading volume of 63,500 shares, compared to its average volume of 65,948. The firm has a market capitalization of $28.04 million, a P/E ratio of -0.93 and a beta of 1.27. The stock has a 50-day simple moving average of $1.60 and a 200-day simple moving average of $1.58. The company has a quick ratio of 2.07, a current ratio of 2.07 and a debt-to-equity ratio of 0.10. Spring Bank Pharmaceuticals has a 1-year low of $0.80 and a 1-year high of $5.70.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in shares of Spring Bank Pharmaceuticals by 34.1% in the fourth quarter. Renaissance Technologies LLC now owns 200,930 shares of the company’s stock worth $317,000 after purchasing an additional 51,130 shares during the period. Exane Derivatives bought a new position in shares of Spring Bank Pharmaceuticals in the first quarter worth about $76,000. JPMorgan Chase & Co. increased its stake in shares of Spring Bank Pharmaceuticals by 190.8% in the first quarter. JPMorgan Chase & Co. now owns 49,492 shares of the company’s stock worth $46,000 after purchasing an additional 32,471 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Spring Bank Pharmaceuticals by 199.0% in the first quarter. Bank of New York Mellon Corp now owns 45,139 shares of the company’s stock worth $42,000 after purchasing an additional 30,043 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Spring Bank Pharmaceuticals by 336.2% in the first quarter. Acadian Asset Management LLC now owns 33,869 shares of the company’s stock worth $31,000 after purchasing an additional 26,105 shares during the period. Institutional investors own 17.43% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.